What Analysts Are Saying About SI-BONE Stock
Portfolio Pulse from Benzinga Insights
SI-BONE Inc (NASDAQ:SIBN), a medical device company, has received mixed analyst ratings over the past three months. Six analysts have provided evaluations, with a shift towards a more bullish sentiment in the last 30 days. The average 12-month price target is $26.00, with a high of $30.00 and a low of $25.00, representing an 11.11% decrease from previous targets. Analysts from Truist Securities, Needham, Cantor Fitzgerald, and Morgan Stanley have adjusted their ratings and price targets, reflecting their views on the company's market conditions and performance. SI-BONE has shown a revenue growth rate of 28.68% as of September 30, 2023, but struggles with a net margin of -29.46% and below-average ROE and ROA.
December 22, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
SI-BONE has received mixed analyst ratings, with a recent trend towards bullishness. The average price target has been reduced by 11.11% to $26.00. The company's strong revenue growth contrasts with its profitability challenges, as indicated by its negative net margin and below-average ROE and ROA.
The mixed analyst ratings and the reduction in the average price target suggest uncertainty, which could lead to a neutral short-term impact on SIBN's stock price. The strong revenue growth is a positive sign, but the concerns about profitability and efficiency metrics may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100